A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations
A study for patients with advanced malignancies (glioma, heme and cholangiocarcinoma or other solid tumors) using study drug IDH305
Sponsor: Novartis Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAO7704
U.S. Govt. ID: NCT02381886
Contact: Gary Schwartz: 212-305-2055 / gks2123@columbia.edu
Additional Study Information: The purpose of this study is to learn whether IDH305 is safe and can have possible benefits for people diagnosed with glioma, cholangiocarcinoma, acute myeloid leukemia (AML), chondrosarcoma or other types of solid tumors and have IDH1R132-mutant tumors cancers that have the IDH1R132 mutation and are not getting better after treatment with currently available treatments, or who cannot tolerate currently available treatments. This study will also help to understand what IDH305 does to your body and assess what your body does to remove the drug.
This study is closed
Investigator
Gary Schwartz, MD
Do You Qualify?
Have you been diagnosed with glioma, cholangiocarcinoma, acute myeloid leukemia (AML) or other types of solid tumors? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Gary Schwartz
gks2123@columbia.edu
212-305-2055
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE